MacroGenics Inc (MGNX)
MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on antibody-based therapeutics for cancer, with its common stock listed on NASDAQ under the ticker MGNX. The company works on discovering, developing, manufacturing, and commercializing treatments in the United States. Its pipeline includes lorigerlimab, a bispecific DART molecule directed at PD-1 and CTLA-4 and being studied in metastatic castration-resistant prostate cancer, as well as in platinum-resistant ovarian cancer and clear cell gynecologic cancer. Additional programs include MGC026, an ADC targeting B7-H3; MGC028, an ADC targeting ADAM9 for solid tumors; and MGC030, an ADC aimed at an undisclosed antigen across several solid tumors. MacroGenics is also developing T-cell engager programs and maintains collaborations with TerSera Therapeutics, Incyte, and Gilead Sciences. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-MGNX
|
$5.02
|
13.6% Upside
|
Fair
|
$6.75
|
52.7% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 11, 2026
|
-4.0x
|
13.3x
|
1.8x
|
274.6 M
|
165.1 M
|
11.7%
|
82.5%
|
-7.2
|
—
|
101.9%
|
